Ethicon US, LLC
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$11Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
44,581clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Stratafix $1.6M associated (2023-2025)
- Vistaseal $1.3M associated (2023-2025)
- Harmonic $1.2M associated (2023-2025)
- Echelon Flex $976K associated (2023-2025)
- Dermabond $890K associated (2023-2025)
- Enseal $796K associated (2023-2025)
- Ethicon $792K associated (2023-2025)
- Echelon; Endopath $758K associated (2023-2025)
- Surgicel Nu-Knit $698K associated (2023-2025)
- Evarrest $636K associated (2023-2025)
- Surgiflo Hemostatic Matrix $538K associated (2023-2025)
- Echelon Endopath $492K associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Philip Woodworth | Lone Tree, CO | Surgery | $257,167.52 |
| John Lipham | Los Angeles, CA | Surgery | $239,622.91 |
| John Ledonne | Baltimore, MD | Surgery | $227,321.11 |
| Grayson Wheatley | Nashville, TN | Thoracic Surgery (Cardiothoracic Vascular Surgery) | $181,899.35 |
| Robert Short | Pittsburgh, PA | Diagnostic Radiology | $153,322.62 |
| Nikolai Bildzukewicz | Los Angeles, CA | Surgery | $153,085.54 |
| Reginald Bell | Lone Tree, CO | Surgery | $140,545.41 |
| Dennis Kraus | New York, NY | Otolaryngology | $114,361.16 |
| Andrew Nunn | Winston Salem, NC | Surgical Critical Care | $97,082.97 |
| Krista Grantham | San Antonio, TX | Surgical | $82,340.09 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.